裂谷热MP-12疫苗在小鼠中引发早期保护性免疫应答
研究用单剂裂谷热病毒MP-12减毒活疫苗腹腔接种CD-1小鼠,于接种后第2、4、5、6、7天以致死剂量强毒攻击,观察存活与中和抗体。结果显示接种后第2天攻击已有部分小鼠存活,第4至7天攻击的小鼠全部存活,存活鼠产生1:80至1:1,280的中和抗体。
要点
- 单剂MP-12疫苗腹腔接种后第2天攻击,部分小鼠已获保护。
- 接种后第4至7天攻击的小鼠全部存活。
- 存活小鼠产生1:80至1:1,280的中和抗体。
核心结论
- 裂谷热MP-12疫苗在小鼠中最早于接种后第2天即引发快速保护性免疫应答,进一步支持该候选疫苗用于预防人和家养反刍动物裂谷热的有效性。
研究设计与样本
- 研究将CD-1小鼠分组,腹腔接种裂谷热MP-12疫苗,并于接种后第2、5、6、7天以致死剂量强毒裂谷热病毒攻击。
- 另设实验用接种MP-12但未攻击的CD-1小鼠观察病毒血症和中和抗体。
主要发现
- 第一项试验中,接种后第2天攻击的3只小鼠有2只存活,第5天和第7天攻击的3只小鼠全部存活。
- 第二项试验每组10只小鼠,接种后第2天攻击的小鼠半数(5只)存活,第4天和第6天攻击的小鼠全部(10只)存活。
- 所有存活动物均产生中和抗体,滴度为1:80至1:1,280。
- 接种MP-12但未攻击的CD-1小鼠在接种后前3天出现低水平病毒血症,接种后第5天至第28天检测到中和抗体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rift Valley fever virus (RVFV) is an important mosquito-borne pathogen that causes outbreaks of severe disease in people and livestock throughout Africa and the Arabian Peninsula. The development of an effective veterinary and human vaccine to protect against Rift Valley fever (RVF) disease remains a high priority. The live attenuated RVFV MP-12 is a promising vaccine candidate for the prevention of RVF in both human and domestic ruminants. The aim of this study was to determine the onset of protective immunity elicted in mice by a single dose of this vaccine. Groups of CD-1 mice were vaccinated intraperitoneally with RVFV MP-12 vaccine and challenged on days 2, 5, 6 and 7 post-vaccination (PV) with a lethal dose of virulent RVFV. The mice were observed once daily for terminal morbidity and blood samples were obtained from the retro-orbital sinus complex on days 23 and 28 PV of surviving mice to determine RVFV neutralizing antibody titers. In one test, 2 of 3 mice challenged on day 2 PV survived and all 3 mice challenged at days 5 and 7 PV also survived. A second test of 10 mice per group was performed, and half (5) of those challenged at day 2 PV survived while all (10) survived challenge at day 4 and 6 PV. All surviving animals develop antibody that ranged from 1:80 to 1:1,280 PV. In a separate experiment, RVFV MP-12 vaccinated CD-1 mice, but not challenged developed a low viremia for the first 3 days PV and neutralzing antibody was detected on days 5 through day 28 PV. These findings demonstrated that the RVFV MP-12 vaccine elicited a rapid protective immune response in mice as early as 2 days PV, thus further supporting the effectiveness of this vaccine candidate for preventing RVF among humans and domestic ruminants.
引用
- Morrill JC, Peters CJ, Bettinger GE, et al. Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice. Vaccine. 2022. PMID: 36333222. doi:10.1016/j.vaccine.2022.10.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。